Ouidad Zehou

Ouidad Zehou

Auto-generated profile, based on publicly available information

Ouidad Zehou

French Network of Rare Skin Cancers, CARADERM, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
OZOuidad Zehou
Ouidad Zehou
CLClaire Leibler
Claire Leibler
JAJean-Philippe Arnault
Jean-Philippe Arnault
JSJohnny Sayegh
Johnny Sayegh
HMHenri Montaudié
Henri Montaudié
CLCéleste Lebbé
Céleste Lebbé
Immune checkpoint inhibitors are new therapeutic options for metastatic melanoma, but little data is available in organ transplant recipient populations. Six French patients, 3 men and 3 women, mean age 66 years (range 44‐74), all kidney transplant recipients, received ipilimumab (CTLA‐4 inhibitor) for metastatic melanoma. At diagnosis of advanced melanoma, immunosuppressive therapy had been minimized in all but one. Adverse effects included one case of grade 1 diarrhea and one grade 1 pruritus. One patient had acute T‐cell‐mediated rejection confirmed by histology, after the first injection of ipilimumab. After a median follow‐up of 4.5 (3‐20) months, one patient achieved partial response, one had stable disease and four had disease progression. All the patients died, 5 from melanoma, 1 from another cause. In this series and in the literature, ipilimumab proves to be safe and possibly active. The acute rejection we encountered was probably related to both a rapid, drastic reduction of immunosuppression and to the use of ipilimumab. Our safety data on ipilimumab contrasts with the organ transplant rejections already reported with PD‐1 inhibitors. We consider that immunosuppression should not be minimized, as the impact on metastatic disease control is probably small.

9 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DBDavid Balakirouchenane
David Balakirouchenane
SGSarah Guégan
Sarah Guégan
CCChantal Csajka
Chantal Csajka
AJAnne Jouinot
Anne Jouinot
VHValentine Heidelberger
Valentine Heidelberger
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relationship for toxicity and efficacy in metastatic melanoma (MM) patients. Univariate Fisher and Wilcoxon models including drug systemic exposure (area under the plasma concentration curve, AUC) were used to identify prognostic factors for the onset of dose-limiting toxicities (DLT), and Cox models for overall (OS) and progression-free survival (PFS). Seventy-three BRAF-mutated patients were included in pharmacokinetic (n = 424, NONMEM) and 52 in pharmacokinetic/pharmacodynamic analyses. Age and sex were identified as determinants of DAB and OHD clearances (p < 0.01). MM patients experiencing DLT were overexposed to DAB compared to patients without DLT (AUC: 9624 vs. 7485 ng∙h/mL, respectively, p < 0.01). Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 2 and plasma ratio AUCOHD/AUCDAB ≥ 1 were independently associated with shorter OS (HR: 6.58 (1.29–33.56); p = 0.023 and 10.61 (2.34–48.15), p = 0.022, respectively). A number of metastatic sites ≥3 and cerebral metastases were associated with shorter PFS (HR = 3.25 (1.11–9.50); p = 0.032 and HR = 1.23 (1.35–10.39), p = 0.011; respectively). TRA plasma exposure was neither associated with toxicity nor efficacy. Our results suggest that early drug monitoring could be helpful to prevent the onset of DLT in MM patients, especially in fragile patients such as the elderly. Regarding efficacy, the clinical benefit to monitor plasma ratio AUCOHD/AUCDAB deserves more investigation in a larger cohort of MM patients.

1 February 2021 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
TDTu Anh Duong
Tu Anh Duong
GLGuillaume Lamé
Guillaume Lamé
OZOuidad Zehou
Ouidad Zehou
Charbel SkayemCharbel Skayem
Charbel Skayem
PMPatricia Monnet
Patricia Monnet
MJMarija Jankovic
Marija Jankovic


29 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
EDEmmanuelle Diaz
Emmanuelle Diaz
CBChristina Bergqvist
Christina Bergqvist
BPBastien Peiffer
Bastien Peiffer
LFLaura Fertitta
Laura Fertitta
AJArnaud Jannic
Arnaud Jannic
PWPierre Wolkenstein
Pierre Wolkenstein

25 January 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
CGChloé Grolleau
Chloé Grolleau
AWAnouk Walter-Petrich
Anouk Walter-Petrich
Nicolas DupinNicolas Dupin
Nicolas Dupin
JCJohan Chanal
Johan Chanal
OZOuidad Zehou
Ouidad Zehou
Céleste LebbéCéleste Lebbé
Céleste Lebbé
Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines are lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin and low-dose interferon had good overall response rates for nonimmunodeficient KS with acceptable tolerance profiles. In addition, we highlighted the aggressiveness of endemic KS compared with classic KS with a higher risk of dissemination and response depletion as progression proceeded.